Also points to a potential advantage for achieving shorter duration from administration to peak factor activity levels & subsequent steady-state i.e. the clock can start earlier in terms of the 52-week period to generate primary evidence of durability.
Of course, we'll have to wait and see what is ultimately determined by FDA for HemoA versus this HemoB program, but again, if Hemo A were to be treated consistent w/ this announcement by Uniqure then...
- it points to a potential advantage for having a short/the shortest duration from time of administration to achieving peak levels of factor activity for HemoA gene therapy.